Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HPV16 genetic variation provides evidence of positive natural selection driven by HLA class I.

Nature communications·2026
Same author

A high-penetrance intergenic variant at 9p21 confers melanoma susceptibility.

Research square·2026
Same author

Co-occurring clonal hematopoiesis exhibits strong selection and high leukemia risk.

Nature communications·2026
Same author

Genetic Determinants of Spontaneous Hepatitis B Surface Antigen Seroclearance and Its Associated Viral Markers.

Alimentary pharmacology & therapeutics·2026
Same author

World Health Organization classification of tumours of the breast 6th edition 2026.

Histopathology·2026
Same author

Calcification and tumour-infiltrating lymphocytes predict upgrade of human epidermal growth factor 2 (HER2)-negative ductal carcinoma in situ diagnosed on core needle biopsy.

Histopathology·2026

Related Experiment Video

Updated: May 23, 2026

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

Integrating In Situ Immune Expression Landscape with Gene Expression-Based Subtyping to Characterize Breast Cancer

Mustapha Abubakar1, Hela Koka1, Priscilla Ming Yi Lee2

  • 1National Cancer Institute Bethesda, MD United States.

Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology
|May 22, 2026
PubMed
Summary
This summary is machine-generated.

Immunohistochemistry (IHC) can classify breast cancer immune subtypes, mirroring RNA sequencing findings. This approach aids in refining subtype stratification and clinical decisions, especially in resource-limited settings.

More Related Videos

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

Related Experiment Videos

Last Updated: May 23, 2026

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

Area of Science:

  • Oncology
  • Immunology
  • Biomarkers

Background:

  • Previous RNA sequencing identified three immune subtypes (low-TIL, high-TIL, high-ISG) in luminal breast cancer.
  • The study investigated if immunohistochemistry (IHC) could replicate these immune classifications.

Purpose of the Study:

  • To determine if standard IHC can capture immune heterogeneity across intrinsic breast cancer subtypes.
  • To assess the utility of IHC panels for immune classification in clinical settings.

Main Methods:

  • 148 invasive breast cancer patients' tumors were analyzed using dual IHC staining for eight immune markers and pan-cytokeratin.
  • Digital image analysis quantified immune-positive cells in stromal regions.

Main Results:

  • IHC marker expression strongly correlated with gene expression-based immune and intrinsic subtypes.
  • High-TIL and high-ISG tumors exhibited higher expression of CD3, CD8, CD20, PDL1, and IDO1 compared to low-TIL tumors.
  • Immune infiltration correlated more with aggressive tumor features (grade, recurrence risk, TP53 mutations) than ER/PR expression.

Conclusions:

  • Immunohistochemistry panels can effectively classify breast cancer immune subtypes.
  • These findings support IHC's potential role in refining subtype stratification and guiding clinical decisions, particularly in resource-limited environments.